Developer docs
API playgroundTry for free, no card

Search company profiles

CogniVue

Full company profile

uuid0008s1n

Namestring
CogniVue
Legal namestring
Cognivue, Inc.
Websiteurl
cognivue.com
Company typeenum
Private
Founded yearint
2009
Descriptiontext

Cognivue, Inc. is a privately held neuroscience technology company headquartered in Victor, New York, founded in 2009 and operating with 11-50 employees. The company develops FDA-cleared digital cognitive assessment devices built on a proprietary adaptive psychophysics platform, serving US-based healthcare providers (physicians, audiologists, and pharmacists) and patients seeking cognitive health monitoring. Its mission is to enable earlier detection of cognitive impairment so that modifiable risk factors can be addressed sooner.

The product portfolio centers on two hardware devices: Cognivue Clarity, a 10-minute self-administered assessment evaluating four cognitive domains (memory, executive function/attention, discrimination, visuospatial) plus two performance parameters, and Cognivue Thrive, a 5-minute abbreviated screening tool evaluating three cognitive domains (memory, visuospatial, executive function). Both use the proprietary CogniWheel single-point patient interface and capture over 130,000 data points per assessment. A patent-pending add-on module, the Cognivue Amyloid Risk Measure (CARM), applies machine learning to age plus three Clarity subtests to generate a four-point amyloid risk score for Alzheimer's risk stratification.

The business model is hardware sales of Clarity and Thrive to healthcare providers, supplemented by a per-use reimbursement pathway enabled by a distinct CPT procedural code created by the American Medical Association in 2019. Cognivue runs an enterprise field-sales motion across three verticals (physician practices, hearing healthcare, community pharmacy) with the EXCEL practice integration program, and a community-led motion anchored by participation in the FOCUS, Bio-Hermes-001, and Bio-Hermes-002 clinical studies alongside partners including Biogen, Eli Lilly, Roche, Sanofi, and the Global Alzheimer's Platform Foundation. The company is led by President and CEO Paul W. Estes and operates exclusively in the United States.

Short descriptiontext

Cognivue, Inc. is a privately held US neuroscience technology company that sells FDA-cleared, self-administered digital cognitive assessment devices (Clarity and Thrive) built on adaptive psychophysics to physicians, audiologists, and pharmacists for early detection of cognitive impairment.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersGatineau, Canada
HQ citystring
Gatineau
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
digital cognitive assessment, computerized cognitive screening, FDA cleared neurology device, Alzheimer early detection, adaptive psychophysics testing
Industry1 code
PRIMARYHLACANAI
Behavioral Health & Neurocognitive Therapeutics (Digital)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
NAICS code1 code
  • Software Publishers5132
SIC code1 code
  • Services-Prepackaged Software7372
Product category
Cognitive Assessment Medical Devices
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Device Sales and Reimbursement
TypeHardware Sales
Description

Cognivue Clarity and Thrive devices are sold to healthcare providers (physicians, audiologists, pharmacists). Insurance companies reimburse providers for two aspects: use of the Cognivue Clarity test itself (distinct CPT procedural code created in 2019) and time spent integration and interpretation of results into patient care including evaluation, clinical decision making, and treatment planning.

cognivue.com
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure
Pricing details2 tiers
1Insurance Reimbursement - Test Administration
ModelOtherBilling cadencePer use
Notes

American Medical Association created a distinct procedural code in 2019 to reimburse providers for administration of neuropsychological testing. Exact reimbursement rates vary by payer.

cognivue.com
2Insurance Reimbursement - Interpretation Services
ModelOtherBilling cadencePer use
Notes

Reimbursement for time spent integration and interpretation of test results including evaluation, clinical decision making, treatment planning, and giving feedback to patients and caregivers.

cognivue.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Cognivue Clarity®
Description

10-minute self-administered computerized cognitive assessment device for physicians that evaluates 4 cognitive domains: memory, executive function/attention, discrimination, and visuospatial.

cognivue.com
+2 more records
Core offering1 text field

CogniVue sells FDA-cleared, self-administered digital cognitive assessment hardware devices—Cognivue Clarity (10-minute, four-domain) and Cognivue Thrive (5-minute, three-domain)—to healthcare providers, using proprietary adaptive psychophysics that collects 130,000+ data points per test. The portfolio is augmented by the patent-pending Cognivue Amyloid Risk Measure (CARM) machine-learning algorithm and the patient-facing Cogniwell Lifestyle program for managing modifiable cognitive risk factors.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Cognivue is as effective as MoCA while demonstrating better test-retest reliability
+5 more records
Product overview1 text field

CogniVue offers a digital cognitive assessment platform based on proprietary FDA-cleared technology using adaptive psychophysics. The portfolio includes two main FDA-cleared assessment devices: Cognivue Clarity (a 10-minute comprehensive cognitive assessment tool evaluating 4 domains plus performance parameters) and Cognivue Thrive (a 5-minute abbreviated screening tool evaluating 3 domains). Both devices collect 130,000+ data points per test and use the CogniWheel interface for patient interaction. An add-on feature called the Cognivue Amyloid Risk Measure (CARM) uses machine learning to predict amyloid presence for Alzheimer's risk stratification. CogniWell Lifestyle provides patient education on lifestyle factors affecting cognitive health.

Product and service3 records
1Cognivue Clarity Device
CategoryCognitive Assessment Device (Physicians)
Description

A 10-minute, self-administered computerized cognitive assessment device based on FDA-cleared technology, evaluating 4 cognitive domains (memory, executive function/attention, discrimination, and visuospatial) plus two performance parameters and collecting over 130,000 data points per patient via adaptive psychophysics. Sold to physician practices through enterprise field sales with EXCEL practice-integration support.

2Cognivue Thrive Device
CategoryCognitive Assessment Device (Hearing Healthcare / Pharmacy)
Description

A 5-minute, self-administered computerized cognitive screening device using the same FDA-cleared adaptive psychophysics technology as Cognivue Clarity, evaluating 3 cognitive domains (memory, visuospatial, executive function) plus two performance parameters. Designed for hearing healthcare providers and community pharmacies to deliver quick cognitive screening in busy office and pharmacy workflows.

3Cogniwell Lifestyle Program
CategoryPatient Cognitive Health Program
Description

A patient-facing lifestyle and education program that delivers evidence-based guidance on managing modifiable risk factors for cognitive health, covering mental fitness, social connections, exercise, nutrition, sleep, hearing health, vision care, and medication management. Aimed at patients who want to understand and proactively manage cognitive health.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-18
Description

Sanofi joined as newest partner in Bio-Hermes-002 observational study evaluating blood-based and digital biomarkers alongside imaging to improve prediction, detection, and diagnosis of Alzheimer's disease. Sanofi will analyze additional biomarkers to augment the study's existing database.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-10-30
Description

Strategic partnership for Bio-Hermes-002 longitudinal study investigating digital and blood-based biomarkers in relationship to tau and amyloid PET imaging. Cognivue Clarity is one of the digital biomarkers being evaluated. Study builds on Bio-Hermes-001 findings. Cognivue joins existing GAP partners including Biogen and other pharmaceutical/diagnostic companies.

3DigiCARE Realized
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-08-02
Description

Strategic partnership to improve routine brain care across healthcare systems, focusing on earlier detection of Alzheimer's disease and related dementias (ADRD). Combines two transformative cognitive assessment technologies following landmark FDA approval of Leqembi.

cognivue.com
4The Kutcher Clinic for Sports Neurology
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-07-12
Description

First-of-its-kind large-scale concussion study conducted by The Kutcher Clinic evaluating and refining how concussions are identified and treated using evidence-based diagnostic inputs including Cognivue technology.

cognivue.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-06-08
Description

Partnership for grant program - one of twelve recipients of inaugural Global Davos Alzheimer's Collaborative Grant Program for Healthcare System Preparedness. Launching innovative early detection program for Alzheimer's in pharmacies nationwide.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Existing GAP partner in Bio-Hermes-001 and Bio-Hermes-002 studies. Biogen is one of the strategic partners collaborating on the Bio-Hermes clinical trial program.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Existing GAP partner in Bio-Hermes studies. Part of the pharmaceutical and diagnostics partner network.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Existing GAP partner in Bio-Hermes studies. Part of the pharmaceutical and diagnostics partner network.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Digital cognitive assessment using smartphone-based AR/AI tasks to detect early signs of cognitive impairment and MCI/AD risk; competes for the same early-detection positioning with a non-hardware delivery model.

TypeDirect peer
Description

Digital cognitive assessment company whose CANTAB platform directly competes with Cognivue Clarity/Thrive; both companies are co-participants in the Bio-Hermes-002 study evaluating digital biomarkers against imaging.

TypeDirect peer
Description

Digital cognitive assessment platform (DCTclock and related tools) targeting early detection of cognitive impairment and Alzheimer's; co-participant with Cognivue in Bio-Hermes-002.

TypeDirect peer
Description

Tablet- and web-based cognitive assessment platform used by clinicians for cognitive impairment screening; targets the same primary-care and specialty physician channel as Cognivue Clarity.

TypeDirect peer
Description

Computerized neurocognitive assessment battery widely used by clinicians and researchers; competes in the same computerized cognitive testing category as Cognivue Clarity.

TypeOthers
Description

The Montreal Cognitive Assessment paper test against which Cognivue benchmarks itself; represents the incumbent cognitive screening standard that Cognivue aims to displace digitally.

TypeDirect peer
Description

Commercial provider of computerized cognitive tests used in clinical trials and healthcare; overlapping product category with Cognivue's adaptive testing, including FDA-cleared elements and pharma trial deployment.

TypeDirect peer
Description

Digital cognitive health company offering computerized assessments for early detection of memory impairment and Alzheimer's; addresses overlapping primary-care and consumer use cases as Cognivue.

TypeOthers
Description

Blood-based biomarker developer (Simoa platform) co-participant in Bio-Hermes-002 alongside Cognivue; represents an alternative (blood-based) modality for early AD detection that may complement or compete with CARM.

TypeOthers
Description

Non-profit clinical trial infrastructure that convenes Cognivue, Biogen, Sanofi, Roche, Eli Lilly, and digital biomarker peers in the Bio-Hermes studies; ecosystem partner rather than a competitor.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CogniVue

Cognitive Assessment Medical Devicescognivue.com

Cognivue, Inc. is a privately held US neuroscience technology company that sells FDA-cleared, self-administered digital cognitive assessment devices (Clarity and Thrive) built on adaptive psychophysics to physicians, audiologists, and pharmacists for early detection of cognitive impairment.

What CogniVue does

Cognivue, Inc. is a privately held neuroscience technology company headquartered in Victor, New York, founded in 2009 and operating with 11-50 employees. The company develops FDA-cleared digital cognitive assessment devices built on a proprietary adaptive psychophysics platform, serving US-based healthcare providers (physicians, audiologists, and pharmacists) and patients seeking cognitive health monitoring. Its mission is to enable earlier detection of cognitive impairment so that modifiable risk factors can be addressed sooner.

The product portfolio centers on two hardware devices: Cognivue Clarity, a 10-minute self-administered assessment evaluating four cognitive domains (memory, executive function/attention, discrimination, visuospatial) plus two performance parameters, and Cognivue Thrive, a 5-minute abbreviated screening tool evaluating three cognitive domains (memory, visuospatial, executive function). Both use the proprietary CogniWheel single-point patient interface and capture over 130,000 data points per assessment. A patent-pending add-on module, the Cognivue Amyloid Risk Measure (CARM), applies machine learning to age plus three Clarity subtests to generate a four-point amyloid risk score for Alzheimer's risk stratification.

The business model is hardware sales of Clarity and Thrive to healthcare providers, supplemented by a per-use reimbursement pathway enabled by a distinct CPT procedural code created by the American Medical Association in 2019. Cognivue runs an enterprise field-sales motion across three verticals (physician practices, hearing healthcare, community pharmacy) with the EXCEL practice integration program, and a community-led motion anchored by participation in the FOCUS, Bio-Hermes-001, and Bio-Hermes-002 clinical studies alongside partners including Biogen, Eli Lilly, Roche, Sanofi, and the Global Alzheimer's Platform Foundation. The company is led by President and CEO Paul W. Estes and operates exclusively in the United States.

CogniVue firmographics

Firmographics
Name
CogniVue
Legal name
Cognivue, Inc.
Website
https://cognivue.com
Company type
Private
Founded year
2009
Operating status
Operating
Headcount range
11–50 employees
Short description
Cognivue, Inc. is a privately held US neuroscience technology company that sells FDA-cleared, self-administered digital cognitive assessment devices (Clarity and Thrive) built on adaptive psychophysics to physicians, audiologists, and pharmacists for early detection of cognitive impairment.
Ownership category
akta.pro rank

CogniVue industry classification

Industry
Product category
Cognitive Assessment Medical Devices
NAICS
Software Publishers (5132)
SIC
Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHLACANAI
Behavioral Health & Neurocognitive Therapeutics (Digital)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)

Keywords

  • Digital cognitive assessment
  • Computerized cognitive screening
  • FDA cleared neurology device
  • Alzheimer early detection
  • Adaptive psychophysics testing

Where CogniVue is headquartered

Location

Headquarters

HQ city
Gatineau
HQ country
Canada
HQ region
North America

Offices2 records

Markets served

CogniVue business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Device Sales and Reimbursement: Cognivue Clarity and Thrive devices are sold to healthcare providers (physicians, audiologists, pharmacists). Insurance companies reimburse providers for two aspects: use of the Cognivue Clarity test itself (distinct CPT procedural code created in 2019) and time spent integration and interpretation of results into patient care including evaluation, clinical decision making, and treatment planning.

Pricing tiers

ModelBillingPrice
OtherPer useInsurance Reimbursement - Test Administration
OtherPer useInsurance Reimbursement - Interpretation Services

Go-to-market motion2 records

Distribution channels3 records

Marketing channels9 records

CogniVue product offering

Product offering

Core offering

CogniVue sells FDA-cleared, self-administered digital cognitive assessment hardware devices—Cognivue Clarity (10-minute, four-domain) and Cognivue Thrive (5-minute, three-domain)—to healthcare providers, using proprietary adaptive psychophysics that collects 130,000+ data points per test. The portfolio is augmented by the patent-pending Cognivue Amyloid Risk Measure (CARM) machine-learning algorithm and the patient-facing Cogniwell Lifestyle program for managing modifiable cognitive risk factors.

Product overview

CogniVue offers a digital cognitive assessment platform based on proprietary FDA-cleared technology using adaptive psychophysics. The portfolio includes two main FDA-cleared assessment devices: Cognivue Clarity (a 10-minute comprehensive cognitive assessment tool evaluating 4 domains plus performance parameters) and Cognivue Thrive (a 5-minute abbreviated screening tool evaluating 3 domains). Both devices collect 130,000+ data points per test and use the CogniWheel interface for patient interaction. An add-on feature called the Cognivue Amyloid Risk Measure (CARM) uses machine learning to predict amyloid presence for Alzheimer's risk stratification. CogniWell Lifestyle provides patient education on lifestyle factors affecting cognitive health.

Differentiator

Problem solved

Functional benefit

Brands

  • Cognivue Clarity®: 10-minute self-administered computerized cognitive assessment device for physicians that evaluates 4 cognitive domains: memory, executive function/attention, discrimination, and visuospatial.
  • Cognivue Thrive®
  • Cogniwell®

Products and services

  • Cognivue Clarity Device A 10-minute, self-administered computerized cognitive assessment device based on FDA-cleared technology, evaluating 4 cognitive domains (memory, executive function/attention, discrimination, and visuospatial) plus two performance parameters and collecting over 130,000 data points per patient via adaptive psychophysics. Sold to physician practices through enterprise field sales with EXCEL practice-integration support.
  • Cognivue Thrive Device A 5-minute, self-administered computerized cognitive screening device using the same FDA-cleared adaptive psychophysics technology as Cognivue Clarity, evaluating 3 cognitive domains (memory, visuospatial, executive function) plus two performance parameters. Designed for hearing healthcare providers and community pharmacies to deliver quick cognitive screening in busy office and pharmacy workflows.
  • Cogniwell Lifestyle Program A patient-facing lifestyle and education program that delivers evidence-based guidance on managing modifiable risk factors for cognitive health, covering mental fitness, social connections, exercise, nutrition, sleep, hearing health, vision care, and medication management. Aimed at patients who want to understand and proactively manage cognitive health.

Quantifiable outcome

  • Cognivue is as effective as MoCA while demonstrating better test-retest reliability
  • +5 more outcomes

Companies that use CogniVue

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles3 records

CogniVue technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature5 records

CogniVue partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and minor.

  • SanoficoreStrategic or Co-development Partner · 18 May 2026Sanofi joined as newest partner in Bio-Hermes-002 observational study evaluating blood-based and digital biomarkers alongside imaging to improve prediction, detection, and diagnosis of Alzheimer's disease. Sanofi will analyze additional biomarkers to augment the study's existing database.
  • Global Alzheimer's Platform Foundation (GAP)coreStrategic or Co-development Partner · 30 October 2024Strategic partnership for Bio-Hermes-002 longitudinal study investigating digital and blood-based biomarkers in relationship to tau and amyloid PET imaging. Cognivue Clarity is one of the digital biomarkers being evaluated. Study builds on Bio-Hermes-001 findings. Cognivue joins existing GAP partners including Biogen and other pharmaceutical/diagnostic companies.
  • DigiCARE RealizedcoreStrategic or Co-development Partner · 2 August 2023Strategic partnership to improve routine brain care across healthcare systems, focusing on earlier detection of Alzheimer's disease and related dementias (ADRD). Combines two transformative cognitive assessment technologies following landmark FDA approval of Leqembi.
  • The Kutcher Clinic for Sports NeurologyminorStrategic or Co-development Partner · 12 July 2023First-of-its-kind large-scale concussion study conducted by The Kutcher Clinic evaluating and refining how concussions are identified and treated using evidence-based diagnostic inputs including Cognivue technology.
  • Avant InstituteminorStrategic or Co-development Partner · 8 June 2022Partnership for grant program - one of twelve recipients of inaugural Global Davos Alzheimer's Collaborative Grant Program for Healthcare System Preparedness. Launching innovative early detection program for Alzheimer's in pharmacies nationwide.
  • BiogencoreStrategic or Co-development PartnerExisting GAP partner in Bio-Hermes-001 and Bio-Hermes-002 studies. Biogen is one of the strategic partners collaborating on the Bio-Hermes clinical trial program.
  • Eli LillycoreStrategic or Co-development PartnerExisting GAP partner in Bio-Hermes studies. Part of the pharmaceutical and diagnostics partner network.
  • RochecoreStrategic or Co-development PartnerExisting GAP partner in Bio-Hermes studies. Part of the pharmaceutical and diagnostics partner network.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

CogniVue competitors and assessment

Company assessment

Direct peers

  • Altoida: Digital cognitive assessment using smartphone-based AR/AI tasks to detect early signs of cognitive impairment and MCI/AD risk; competes for the same early-detection positioning with a non-hardware delivery model.
  • Cambridge Cognition: Digital cognitive assessment company whose CANTAB platform directly competes with Cognivue Clarity/Thrive; both companies are co-participants in the Bio-Hermes-002 study evaluating digital biomarkers against imaging.
  • Linus Health: Digital cognitive assessment platform (DCTclock and related tools) targeting early detection of cognitive impairment and Alzheimer's; co-participant with Cognivue in Bio-Hermes-002.
  • BrainCheck: Tablet- and web-based cognitive assessment platform used by clinicians for cognitive impairment screening; targets the same primary-care and specialty physician channel as Cognivue Clarity.
  • CNS Vital Signs: Computerized neurocognitive assessment battery widely used by clinicians and researchers; competes in the same computerized cognitive testing category as Cognivue Clarity.
  • Cogstate: Commercial provider of computerized cognitive tests used in clinical trials and healthcare; overlapping product category with Cognivue's adaptive testing, including FDA-cleared elements and pharma trial deployment.
  • Neurotrack: Digital cognitive health company offering computerized assessments for early detection of memory impairment and Alzheimer's; addresses overlapping primary-care and consumer use cases as Cognivue.

Others

  • MoCA Test: The Montreal Cognitive Assessment paper test against which Cognivue benchmarks itself; represents the incumbent cognitive screening standard that Cognivue aims to displace digitally.
  • Quanterix (Lucent Diagnostics): Blood-based biomarker developer (Simoa platform) co-participant in Bio-Hermes-002 alongside Cognivue; represents an alternative (blood-based) modality for early AD detection that may complement or compete with CARM.
  • Global Alzheimer's Platform (GAP) Foundation: Non-profit clinical trial infrastructure that convenes Cognivue, Biogen, Sanofi, Roche, Eli Lilly, and digital biomarker peers in the Bio-Hermes studies; ecosystem partner rather than a competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

CogniVue social profiles

Digital presence

CogniVue financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CogniVue leadership team

Management profile

Number of profiles

Profiles7 records

CogniVue funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CogniVue M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CogniVue

What does CogniVue do?

CogniVue sells FDA-cleared, self-administered digital cognitive assessment hardware devices—Cognivue Clarity (10-minute, four-domain) and Cognivue Thrive (5-minute, three-domain)—to healthcare providers, using proprietary adaptive psychophysics that collects 130,000+ data points per test. The portfolio is augmented by the patent-pending Cognivue Amyloid Risk Measure (CARM) machine-learning algorithm and the patient-facing Cogniwell Lifestyle program for managing modifiable cognitive risk factors.

Is CogniVue a public or private company?

CogniVue is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was CogniVue founded?

CogniVue was founded in 2009. It employs 11 to 50 people.

Where is CogniVue based?

CogniVue is headquartered in Gatineau, Canada, in the North America region.

How does CogniVue make money?

One revenue line is on record: device Sales and Reimbursement.

Who are CogniVue's main competitors?

Direct peers on record are Altoida, Cambridge Cognition, Linus Health, BrainCheck, CNS Vital Signs, Cogstate and Neurotrack. Others are MoCA Test, Quanterix (Lucent Diagnostics) and Global Alzheimer's Platform (GAP) Foundation.

Does CogniVue have an API?

No public API is recorded for CogniVue.

What industry is CogniVue in?

CogniVue's product category is Cognitive Assessment Medical Devices. Its primary akta.pro industry code is HLACANAI, Behavioral Health & Neurocognitive Therapeutics (Digital). Its NAICS code is 5132 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comCognitive Diagnostics Market Analysis, Share, Trend, Industry Report Forecast till 2032 | Cognetivity Neurosciences, Cognivue, IncThe global cognitive diagnostics market is projected to grow from USD 120.4 billion in 2025 to USD 259.8 billion by 2032, a CAGR of 8.1%. Growth is driven by an aging population and rising demand for Alzheimer's diagnostics. IBM Watson Health holds a 25-30% share, with Google Health as a major competitor.INVISIONMAG.COMCognivue Appoints Jason Agran, MD, PhD, as Chief Medical Officer and Senior Vice PresidentCognivue appointed Jason Agran, MD, PhD, as chief medical officer and senior vice president, effective February 7, 2022. He succeeds Fred Ma, who is retiring, and brings experience in neurosurgery, neuroimaging, and emergency medicine. He will split time between Georgia and Rochester, NY.PR NewswireCognivue Appoints Dr. Fred Ma as Chief Medical Officer & Senior Vice PresidentCognivue, Inc. appointed Dr. Fred Ma as Chief Medical Officer and Senior Vice President, effective immediately. Dr. Ma brings nearly four decades of experience in global medical device and pharmaceutical development, including leadership roles at GE Healthcare, Johnson & Johnson, and Merck, as well as prior positions as a practicing neurosurgeon in Beijing and Tokyo. The company expects his expertise to support product development and extend clinical validation for Cognivue's FDA-cleared computerized cognitive assessment technologies.PR Newswire APACCogniVue and NeoLAB Convergence Inc. Announce N2 Smart Pen using CogniVue APEX Image Cognition Processor TechnologyCogniVue and NeoLAB Convergence announced the N2 smartpen, integrating CogniVue's APEX Image Cognition Processor (CV2201) for performance and battery life. The pen offers 256 pressure steps, 120 fps, and auto power management. The collaboration aims to redefine smartpen capabilities.EetimesEE Times Silicon 60: Hot Startups to WatchEE Times updated its Silicon 60 list to version 15.1, adding 38 newly formed companies and removing 38 others. The new firms span materials, IP cores, memory, processors, wireless, and IoT, while the list has been published since 2004.CNETFreescale vision chip makes self-driving cars a bit more ordinaryFreescale Semiconductor partnered with Neusoft and Green Hills Software to develop an automotive vision chip for driver-assistance features like pedestrian detection and drowsy-driver alerts. The chip, licensed from CogniVue, has 64 computing engines and is set to launch in 2015, with upgrades in 2016 and 2017.